<DOC>
	<DOCNO>NCT00055614</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness topotecan treating patient advance ovarian epithelial , fallopian tube , primary peritoneal cancer .</brief_summary>
	<brief_title>Topotecan Treating Patients With Advanced Ovarian Epithelial , Fallopian Tube , Primary Peritoneal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose duration prolong topotecan maintenance patient advance ovarian epithelial , fallopian tube , primary peritoneal cancer complete clinical response platinum-based chemotherapy . - Determine safety regimen patient . OUTLINE : This dose-escalation study . Patients receive oral topotecan twice daily 21 day . Treatment repeat every 28 day 6 month absence unacceptable toxicity disease progression . Patients tolerate course 1 may receive escalate dose topotecan subsequent course . The maximum tolerate dose define dose tolerated majority patient . Patients follow every 2 month least 6 month . PROJECTED ACCRUAL : A total 20 patient accrue study .</detailed_description>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm ovarian epithelial , fallopian tube , primary peritoneal serous cancer Stage IIIB , IIIC , IV Surgically stag debulked Complete clinical response firstline platinumbased chemotherapy ( cisplatin carboplatin ) define follow criterion : No evidence cancer history physical examination CA 125 great 35 units/mL No evidence residual cancer CT scan abdomen/pelvis chest xray Must receive least 5 course firstline chemotherapy PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy Not specify Hematopoietic Granulocyte count least 1,200/mm^3 Platelet count least 90,000/mm^3 Hepatic Bilirubin normal ALT AST less 1.5 time upper limit normal ( ULN ) Alkaline phosphatase le 1.5 ULN Renal Creatinine clearance least 60 mL/min PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent immunotherapy Chemotherapy See Disease Characteristics At least 3 week since prior firstline chemotherapy At least 3 year since prior chemotherapy ( firstline chemotherapy ovarian , fallopian tube , primary peritoneal cancer ) No concurrent chemotherapy Endocrine therapy No concurrent hormonal therapy Radiotherapy No prior abdominopelvic radiotherapy No concurrent radiotherapy Surgery See Disease Characteristics No concurrent surgery Other No concurrent antitumor therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
</DOC>